News -

Scientific Publication of The Week - The intriguing options of multispecific antibody formats for treatment of cancer


We focus on the achievements and prospects of the underlying technologies for generating bi- and multispecific antibodies to i) target immune effector cells and/or cytokines to tumors, ii) engage death receptors on tumor cells simultaneously, iii) improve antiangiogenic intervention by blocking complementary pathways of angiogenesis and iv) achieve more efficient targeting of human epidermal growth factor-related and other receptor tyrosine kinase-related pathways.

Many of the outlined approaches, in addition to potential improvement of therapeutic efficacy in comparison to single agent intervention, also offer the potential to counteract therapy resistance.

Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U.
Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany.


  • Health, Health Care, Pharmaceuticals


  • bioprocess international conference & exhibition
  • antibody drug conjugates
  • recombinant antibodies
  • roche diagnostic
  • multispecific
  • bispecific
  • roche


Daniel Barry

Press contact Dr BPI Europe Project Manager

Related content